NCT02001818 2024-08-06
PInNACLe
Australasian Leukaemia and Lymphoma Group
Phase 2 Completed
Clinical Trials
27 trialsNCT00574730 2023-09-14
CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma
University of Nebraska
Phase NA Completed
NCT00846430 2023-08-30
Medical Treatment of "High-Risk" Neurofibromas
Corewell Health West
Phase 2 Completed
NCT00049530 2023-06-29
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00134030 2023-06-07
EURAMOS-1
Children's Oncology Group
Phase 3 Completed
NCT02634294 2023-03-16
Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2/3 Completed
NCT02218164 2022-10-07
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02089685 2022-09-13
MK-3475-029
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT00525031 2020-09-23
Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02379195 2020-01-22
Peginterferon and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT03554005 2019-07-15
MK-4031-009
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01933906 2019-01-04
Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 1 Completed
NCT02155322 2018-08-23
A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00014261 2018-03-30
Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT00396019 2017-11-06
Study of PEG-Intron for Plexiform Neurofibromas
University of Pittsburgh
Phase 2 Completed
NCT00457418 2017-06-07
High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00759109 2017-04-07
Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00861406 2017-03-03
Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00548847 2016-10-26
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Emory University
Phase 2 Completed
NCT00050531 2016-05-11
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00303290 2015-11-26
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00045279 2013-06-05
PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00276523 2012-10-31
PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00047879 2011-10-26
Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00623402 2011-01-12
SoraPeg
University Hospital Schleswig-Holstein
Phase 2 Completed
NCT01227356 2010-10-25
A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia
Uppsala University
Phase 2 Completed
NCT00221702 2010-10-13
EADO
University Hospital, Bordeaux
Phase 3 Completed